Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite announced the publication of a peer-reviewed article in Biomolecules Journal validating the broad therapeutic potential of its lead candidates, Piclidenoson and Namodenoson. The review highlights evidence of A3AR agonist activity in treating diverse conditions including solid tumors, MASH, Alzheimer's disease, and osteoarthritis.
Key figures
- Patients in studies
- over 1,600
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.